Improving bone marrow transplants to better fight blood cancers
Targeting alloantigen presentation in bone marrow to enhance graft-versus-leukemia effects
This study is looking at ways to make bone marrow transplants work better for people with blood cancers by boosting the immune system's ability to fight cancer while reducing unwanted side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10997362 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of bone marrow transplants in treating blood cancers by focusing on the immune response. It aims to improve the graft-versus-leukemia (GVL) effects while minimizing harmful side effects like graft-versus-host disease (GVHD). The approach involves understanding the role of specific immune cells in presenting antigens that can help target cancer cells more effectively. By identifying and utilizing these antigen-presenting cells, the research seeks to reduce the risk of cancer relapse after transplantation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing allogeneic bone marrow transplantation for blood cancers.
Not a fit: Patients who are not undergoing bone marrow transplantation or those with conditions unrelated to blood cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective bone marrow transplant procedures that significantly improve survival rates for patients with blood cancers.
How similar studies have performed: Previous research has shown promise in enhancing immune responses in bone marrow transplants, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Koyama, Motoko — Fred Hutchinson Cancer Center
- Study coordinator: Koyama, Motoko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.